Human Investing LLC Reduces Holdings in Gilead Sciences, Inc. $GILD

Human Investing LLC lowered its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 27.6% during the second quarter, HoldingsChannel reports. The firm owned 2,419 shares of the biopharmaceutical company’s stock after selling 924 shares during the period. Human Investing LLC’s holdings in Gilead Sciences were worth $268,000 as of its most recent SEC filing.

A number of other hedge funds also recently made changes to their positions in the company. Jennison Associates LLC purchased a new stake in shares of Gilead Sciences during the second quarter valued at approximately $71,770,000. New York Life Investment Management LLC raised its stake in shares of Gilead Sciences by 0.4% during the second quarter. New York Life Investment Management LLC now owns 187,571 shares of the biopharmaceutical company’s stock valued at $20,796,000 after purchasing an additional 789 shares during the period. Howard Capital Management Inc. raised its stake in shares of Gilead Sciences by 17.1% during the second quarter. Howard Capital Management Inc. now owns 39,094 shares of the biopharmaceutical company’s stock valued at $4,334,000 after purchasing an additional 5,702 shares during the period. Purkiss Capital Advisors LLC purchased a new stake in shares of Gilead Sciences during the second quarter valued at approximately $210,000. Finally, Motley Fool Asset Management LLC raised its stake in shares of Gilead Sciences by 14.9% during the second quarter. Motley Fool Asset Management LLC now owns 81,254 shares of the biopharmaceutical company’s stock valued at $9,009,000 after purchasing an additional 10,554 shares during the period. Hedge funds and other institutional investors own 83.67% of the company’s stock.

Insider Buying and Selling at Gilead Sciences

In other Gilead Sciences news, insider Johanna Mercier sold 3,000 shares of the business’s stock in a transaction on Wednesday, October 15th. The shares were sold at an average price of $118.08, for a total transaction of $354,240.00. Following the completion of the sale, the insider owned 110,193 shares in the company, valued at $13,011,589.44. The trade was a 2.65% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CFO Andrew D. Dickinson sold 2,500 shares of the business’s stock in a transaction on Wednesday, October 15th. The shares were sold at an average price of $118.08, for a total transaction of $295,200.00. Following the sale, the chief financial officer owned 157,055 shares of the company’s stock, valued at approximately $18,545,054.40. The trade was a 1.57% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 61,500 shares of company stock worth $7,142,140 over the last 90 days. Insiders own 0.27% of the company’s stock.

Wall Street Analyst Weigh In

GILD has been the topic of a number of analyst reports. Daiwa America upgraded shares of Gilead Sciences from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, August 19th. Royal Bank Of Canada lifted their price target on shares of Gilead Sciences from $98.00 to $100.00 and gave the stock a “sector perform” rating in a research note on Wednesday, October 8th. JPMorgan Chase & Co. lifted their price target on shares of Gilead Sciences from $135.00 to $145.00 and gave the stock an “overweight” rating in a research note on Tuesday, September 16th. UBS Group lifted their price target on shares of Gilead Sciences from $108.00 to $112.00 and gave the stock a “neutral” rating in a research note on Friday, August 8th. Finally, Cantor Fitzgerald lifted their price target on shares of Gilead Sciences from $129.00 to $135.00 and gave the stock an “overweight” rating in a research note on Thursday, October 9th. One investment analyst has rated the stock with a Strong Buy rating, twenty have given a Buy rating and six have issued a Hold rating to the stock. Based on data from MarketBeat.com, Gilead Sciences currently has a consensus rating of “Moderate Buy” and a consensus price target of $122.61.

Gilead Sciences Stock Down 2.1%

GILD stock opened at $117.88 on Wednesday. The company has a debt-to-equity ratio of 1.13, a current ratio of 1.32 and a quick ratio of 1.15. Gilead Sciences, Inc. has a 1-year low of $86.08 and a 1-year high of $124.61. The firm has a fifty day moving average price of $115.51 and a two-hundred day moving average price of $111.33. The firm has a market cap of $146.27 billion, a price-to-earnings ratio of 23.48, a PEG ratio of 0.83 and a beta of 0.34.

Gilead Sciences (NASDAQ:GILD) last released its earnings results on Thursday, August 7th. The biopharmaceutical company reported $2.01 earnings per share for the quarter, beating the consensus estimate of $1.96 by $0.05. Gilead Sciences had a net margin of 21.86% and a return on equity of 50.99%. The firm had revenue of $7.08 billion during the quarter, compared to analyst estimates of $6.95 billion. During the same quarter in the previous year, the firm earned $2.01 earnings per share. The firm’s revenue for the quarter was up 1.4% compared to the same quarter last year. Gilead Sciences has set its FY 2025 guidance at 7.950-8.250 EPS. Research analysts predict that Gilead Sciences, Inc. will post 7.95 EPS for the current year.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.